Etanercept
Etanercept is a biologic medication that works by blocking tumor necrosis factor (TNF), a protein that drives inflammation in autoimmune diseases. It is prescribed for various inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
A TNF inhibitor biologic used to treat inflammatory autoimmune conditions affecting the joints.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L04AB01
- RxNorm
- 214555
- Generic
- Etanercept
- Class
- atc-l04
- Brands
- Enbrel, Eticovo
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, injection, solution
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 50mg once weekly
- Maximum
- consult physician
- Frequency
- once weekly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.8mg/kg once weekly (max 50mg)
- Maximum
- consult physician
- Frequency
- once weekly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 50mg once weekly
- Maximum
- consult physician
- Frequency
- once weekly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
discontinue therapy prior to conception when possible; use only if benefits outweigh risks
regular fetal monitoring and ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second third trimesteravoid if possible
consider discontinuation in third trimester due to potential immune effects on newborn
fetal growth monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
not recommendeddiscontinue breastfeeding
etaracept is not recommended during breastfeeding; either discontinue drug or discontinue breastfeeding
monitor infant for signs of infection
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly over 65no specific dose adjustment required
use with caution; increased risk of infections; monitor closely for adverse effects
regular monitoring of renal function and infection signs
Use with caution and monitor for adverse effects.
pediatric_age
juvenile idiopathic arthritisweight-based dosing required
approved for patients 2 years and older with moderate to severe polyarticular juvenile idiopathic arthritis; 0.8 mg/kg weekly
monitor for infections and response to therapy
pediatric_age
pediatric psoriasisweight-based dosing required
approved for patients 4 years and older with chronic severe plaque psoriasis; 0.8 mg/kg weekly
regular monitoring for infections and skin response
renal_impairment
mild moderateno dose adjustment required
no dose adjustment needed for mild to moderate renal impairment; monitor renal function
periodic assessment of renal function
Use with caution and monitor for adverse effects.
hepatic_impairment
mild moderateno specific dose adjustment recommended
use with caution; limited clinical experience in hepatic impairment
monitor liver function tests periodically
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Original FDA approval date for Etanercept (Enbrel)
Drug class
Classification as tumor necrosis factor inhibitor
Common uses
FDA-approved indications for Etanercept
Mechanism of action
Biologic mechanism of action
Treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. May also be used for other inflammatory conditions as determined by a physician.
Etanercept is a fusion protein that binds to TNF-alpha, preventing it from activating inflammatory responses and causing joint damage. By neutralizing TNF, it reduces inflammation and helps preserve joint function.
Administered by subcutaneous injection. Increases susceptibility to infections and should not be used during active infections. Live vaccines should be avoided during treatment. Requires regular monitoring by a healthcare provider. May increase risk of certain cancers and blood disorders.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy